Corcept Therapeutics Incorporated
CORT
주식 순위
#1818
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo... Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
주가
$109.25
마지막 동기화: 2026-10-16
시가총액
$11.81B
변동 (1일)
-3.64%
변동 (1년)
38.83%
국가
US
거래 Corcept Therapeutics Incorporated (CORT)
카테고리
Healthcare
Corcept Therapeutics Incorporated (CORT)의 영업이익률
October 2026 기준 영업이익률 TTM: 0.77%
Corcept Therapeutics Incorporated의 최신 재무 보고서와 주가에 따르면 현재 영업이익률 (TTM)은 0.77%입니다. 2023년 말 기준 영업이익률은 22.24%였습니다.
Corcept Therapeutics Incorporated의 영업이익률 기록 (2001 ~ 2026)
매년 말 영업이익률
| 연도 | 영업이익률 | 변화 |
|---|---|---|
| 2026 (TTM) | 0.77% | -96.21% |
| 2024 | 20.29% | -8.77% |
| 2023 | 22.24% | -20.66% |
| 2022 | 28.03% | -17.58% |
| 2021 | 34.01% | -6.13% |
| 2020 | 36.23% | -0.49% |
| 2019 | 36.41% | 2.22% |
| 2018 | 35.62% | 7.29% |
| 2017 | 33.20% | 165.18% |
| 2016 | 12.52% | -282.77% |
| 2015 | -6.85% | -93.41% |
| 2014 | -104.02% | -74.04% |
| 2013 | -400.66% | -63.47% |
| 2012 | -1,096.82% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | -100.00% |
| 2009 | -69,827.59% | 641.22% |
| 2008 | -9,420.57% | 270.82% |
| 2007 | -2,540.46% | -70.80% |
| 2006 | -8,701.36% | 0.00% |
| 2005 | 0.00% | 0.00% |
| 2004 | 0.00% | 0.00% |
| 2003 | 0.00% | 0.00% |
| 2002 | 0.00% | 0.00% |
| 2001 | 0.00% | 0.00% |
유사 기업 또는 경쟁사의 영업이익률
| 회사 | 영업이익률 | 영업이익률 차이 | 국가 |
|---|---|---|---|
| 62.34% | -19.04% |
US
|
|
| 0.00% | - |
SE
|
|
| 0.00% | - |
FR
|
|
| 0.00% | - |
IT
|
|
| 29.76% | -61.35% |
HK
|
회사의 영업이익률이란?
영업이익률은 회사의 수익성을 평가하는 핵심 지표입니다. 높은 영업이익률은 일반적으로 긍정적으로 간주되며, 이는 회사가 제품이나 서비스를 생산 비용보다 훨씬 높은 가격에 판매할 수 있음을 보여줍니다. 영업이익률은 회사의 수익을 매출로 나누어 계산합니다.